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Delineating themechanismormechanisms that regu-
late the specification of hemogenic endothelial cells
from primordial endothelium is critical for optimizing
their derivation from human stem cells for clinical
therapies. We previously determined that retinoic
acid (RA) is required for hemogenic specification,
as well as cell-cycle control, of endothelium during
embryogenesis. Herein, we define the molecular
signals downstream of RA that regulate hemogenic
endothelial cell development and demonstrate that
cell-cycle control is required for this process. We
found that re-expression of c-Kit in RA-deficient
(Raldh2/) primordial endothelium induced Notch
signaling andp27 expression,which restoredcell-cy-
cle control and rescued hemogenic endothelial cell
specification and function. Re-expression of p27 in
RA-deficient and Notch-inactivated primordial endo-
thelial cells was sufficient to correct their defects
in cell-cycle regulation and hemogenic endothelial
cell development. Thus, RA regulation of hemogenic
endothelial cell specification requires c-Kit, notch
signaling, and p27-mediated cell-cycle control.
INTRODUCTION
Multilineage hematopoietic progenitor cells are first generated
from hemogenic endothelial cells of the murine yolk sac at em-
bryonic day (E)8.25, when the primitive vascular plexus is being
remodeled into a circulatory network (Goldie et al., 2008; Nadin
et al., 2003; Silver and Palis, 1997). The specification of arterial,
venous, and hemogenic endothelial cells from primordial endo-
thelium thus occurs simultaneously, coincident with the onset
of cardiac contraction and pulsatile flow (Lucitti et al., 2007).504 Developmental Cell 27, 504–515, December 9, 2013 ª2013 ElsevDelineating the molecular signals that govern specialization of
endothelial cell subtypes is not only important to furthering our
understanding of normal vascular development but also critical
to improving methodologies for the directed differentiation of
vascular cells from human pluripotent stem cells for tissue engi-
neering and regenerative medicine applications.
Although we are now beginning to define the signaling path-
ways that regulate arterial-venous and lymphatic endothelial
specification (reviewed in Atkins et al., 2011), we still know rela-
tively little about the specification of hemogenic endothelial cells.
In previous studies, we defined the in vivo phenotype of yolk
sac hemogenic endothelial cells (Goldie et al., 2008; Nadin
et al., 2003): they express the vascular endothelial growth factor
receptor VEGFR2 (Flk-1) and hematopoietic stem cell (HSC)
marker c-Kit, and they lack expression of blood lineage markers,
including CD45. In addition, hemogenic endothelial cells exhibit
a Hoechst dye-efflux, or SP, phenotype which is characteristic of
adult HSCs and other stem cell populations (Goodell et al., 1996;
Hierlihy et al., 2002; Kubota et al., 2003; Welm et al., 2003; Wulf
et al., 2003). Hemogenic endothelial cells within the murine yolk
sac that demonstrate clonal multilineage hematopoietic poten-
tial are thus defined as Flk-1+c-Kit+CD45 SP cells.
Our previous studies also revealed that retinoic acid (RA)
signaling is required for hemogenic specification (Goldie et al.,
2008), as well as cell-cycle control (Bohnsack et al., 2004; Lai
et al., 2003), of primordial endothelium in vivo. Mice lacking
retinaldehyde dehydrogenase-2 (Raldh2) (Niederreither et al.,
1999), the primary enzyme responsible for embryonic RA gener-
ation, fail to undergo vascular remodeling or develop hemogenic
endothelium and therefore exhibit impaired definitive hemato-
poiesis. The primary vascular defect in Raldh2/ mutants is
endothelial cell hyperproliferation, associated with decreased
expression of the cyclin-dependent kinase inhibitors p21
(Cdkn1a) and p27 (Cdkn1b) (Lai et al., 2003). Also downregulated
in Raldh2/ mutants is c-Kit, the expression of which distin-
guishes primordial from hemogenic endothelial cells, and key
regulators of hematopoiesis, including Runx1 and c-Myb (Goldie
et al., 2008).ier Inc.
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Raldh2/ embryos, either in vivo via maternal feeding (Goldie
et al., 2008; Lai et al., 2003) or ex vivo via whole embryo culture
(Bohnsack et al., 2004; Lai et al., 2003), rescues their defects
in endothelial cell proliferation and restores hemogenic endo-
thelial cell development and subsequent definitive hematopoie-
sis. Thus, this model provides an ideal genetic background
in which to dissect the signaling hierarchy downstream of
RA that promotes the blood-forming potential in primordial
endothelium and in which to ask whether proper endothelial
cell-cycle control is necessary and sufficient for hemogenic
specification.
We previously demonstrated that Raldh2 is expressed in the
E8.5 murine yolk sac visceral endoderm (VE), while RA receptors
(RARa1 and RARa2) are specifically expressed by endothelial
cells within the underlying mesoderm (Bohnsack et al., 2004;
Goldie et al., 2008). In the current study, we used mice in which
the b-galactosidase (b-gal) lacZ reporter is expressed down-
stream of a RA-response element (Rossant et al., 1991) to
demonstrate that RA signaling is largely restricted to endothelial
cells within the E8.5 yolk sac, as predicted by receptor expres-
sion (Bohnsack et al., 2004). Furthermore, 90% of RA-respon-
sive endothelial cells exhibited a hemogenic endothelial cell
phenotype, were enriched for multilineage hematopoietic poten-
tial, and expressed high levels of c-Kit,Runx1, and c-Myb, which
all contain putative RA binding sites in regulatory regions
(Laleve´e et al., 2011).
We investigated whether re-expression of these genes in RA-
deficient primordial endothelium could rescue their hemogenic
specification. We found that c-Kit, specifically, rescued the
development of yolk sac hemogenic endothelial cells and also
upregulated Runx1, which promoted the generation/propaga-
tion of hematopoietic progenitors from hemogenic endothelium.
Notch1 and p27 expression were also upregulated downstream
of c-Kit, and p27 was suppressed when Notch signaling was in-
activated in c-Kit-rescued embryos. Interestingly, re-expression
of p27 (to wild-type levels) in RA-deficient and Notch-inacti-
vated primordial endothelial cells was sufficient to correct cell-
cycle defects and hemogenic specification therein. Thus, our
data indicate that c-Kit and Notch signaling function down-
stream of RA, via p27, to regulate endothelial cell-cycle pro-
gression, which is necessary and sufficient for hemogenic
specification.
RESULTS
Hemogenic Endothelial Cells Are RA Responsive
We previously reported that RA signaling is essential for the for-
mation of yolk sac hemogenic endothelial cells (Goldie et al.,
2008). To demonstrate which cell types exhibit active RA
signaling during hemogenic endothelial cell specification in vivo,
we used RARE-lacZ mice (Rossant et al., 1991). Cross-sections
of X-gal-stained wild-type E8.5 yolk sac (Raldh2+/+; RARE-
lacZ+/) revealedRA-responsive cells lining vascular lumens (Fig-
ure 1A, shown in blue in panel 2). X-gal staining was absent in
wild-type embryos lacking the lacZ transgene (Raldh2+/+;
RARE-lacZ/; Figure 1A, panel 1) and in RA-deficient mutants
expressing the lacZ transgene (Raldh2/; RARE-lacZ+/; Fig-
ure 1A, panel 3). When active RA was provided to RA-deficientDevelopmembryos in utero (Raldh2/; RARE-lacZ+/ + RA), RA signaling
within the endothelium was restored (Figure 1A, panel 4).
To further define the phenotype(s) of RA-responsive cells
(which constituted 3% of total yolk sac cells), b-gal+ cells
were isolated from E8.5 Raldh2+/+; RARE-lacZ+/ yolk sacs
and subjected to antibody staining and fluorescence-activated
cell sorting (FACS). We found that 38.4% ± 0.9% of b-gal+ cells
were CD31+CD45 endothelial cells (Figure 1B, panel 2) and that
90% of those were Flk-1+c-Kit+CD31+CD45 hemogenic
endothelial cells (Figures 1B, panel 3, and 1C). Approximately
55% of the b-gal+ yolk sac cells were CD31+CD45+ blood cells
(data not shown), which were likely derived from hemogenic
endothelium during definitive hematopoiesis, given that RA
signaling does not regulate blood production during primitive
hematopoiesis (Goldie et al., 2008). Of note, CD41 was not
used as a marker to distinguish blood and endothelial cells
because it was heterogeneously expressed in blood, hemogenic
endothelial, and nonhemogenic endothelial cells.
RA-Responsive Endothelial Cells Are Enriched for
Hematopoietic Regulators and Multilineage
Hematopoietic Potential
We performed real-time quantitative PCR (qPCR) on total RNA
isolated from both RA-responsive (b-gal+) and nonresponsive
(b-gal) endothelial cells within E8.5 Raldh2+/+; RARE-lacZ+/
yolk sacs to evaluate their relative expression of hematopoietic
regulators. We observed no significant differences in the expres-
sion of transcription factors GATA-1, GATA-2, Tal-1, or Lmo2
(Figure 1D); however, expression of stem cell factor receptor
c-Kit, and transcription factors Runx1 and c-Myb, was signifi-
cantly upregulated in b-gal+ endothelium. Using colony-forming
assays, we found that lineage-restricted (CFU [colony-forming
units]; 3.7% versus 1.2%, p < 0.0001; Figure 1E, panel 1) and
multilineage (CFU-GEMM; 2.2% versus 0.6%, p < 0.0001; Fig-
ure 1E, panel 2) hematopoietic colony-forming activities were
enriched in b-gal+ versus b-gal endothelial cells.
Lentivirus-Mediated Re-expression of Hematopoietic
Genes in Raldh2–/– Primordial Endothelium
To investigate whether c-Kit, Runx1, or c-Myb functions down-
stream of RA signaling to promote hemogenic endothelial cell
specification, cDNA encoding each gene was cloned upstream
of a lentiviral IRES-ZsGreen1 reporter, under the control of the
cytomegalovirus promoter (Figure 2A). A constitutively active
promoter was used because there is no known promoter for pri-
mordial endothelium that is homogeneously expressed at E7.5
(Argraves and Drake, 2005). We infected cultured E7.5–E8.0
Raldh2/ mutants with each lentivirus (LV) to restore candidate
gene expression within primordial yolk sac endothelium during
the time frame of hemogenic endothelial cell specification.
Localization of ZsGreen1 expression revealed successful
infection of endothelial cells with c-Kit-expressing LV (Figure 2B,
c-Kit LV). FACS analysis revealed that, 48 hr postinfection, >30%
of ZsGreen1+ yolk sac cells were CD31+CD45 endothelial cells,
a further 10% were Flk-1+c-Kit+CD45 SP hemogenic endothe-
lial cells, and45%were CD31+CD45+ blood cells (summarized
in Figure 2C). The ZsGreen1+ hemogenic endothelial and blood
cells were presumably generated from the infected primordial
endothelium, given the absence of hemogenic endothelial cellsental Cell 27, 504–515, December 9, 2013 ª2013 Elsevier Inc. 505
Figure 1. Endothelial Cells of the Murine Yolk Sac Respond to Active RA Signaling at the Onset of Definitive Hematopoiesis and Display En-
riched Hematopoietic Colony-Forming Activity In Vitro and Upregulated Expression of Hematopoietic Genes
(A) Cross-sections of E8.5 yolk sac tissues showing blue-stained endothelial cells expressing b-gal in concepti expressing the RARE-lacZ transgene (Raldh2+/+;
RARE-lacZ+/; and Raldh2/; RARE-lacZ+/ + RA). Blue staining is not observed in wild-type yolk sac tissues when the lacZ transgene is absent (Raldh2+/+;
RARE-lacZ/) or when RA signaling is impaired (Raldh2/; RARE-lacZ+/). Scale bars in all panels, 20 mm.
(B) FACS analysis of b-gal+ cells, primordial endothelial cells (CD31+CD45), and hemogenic endothelial cells (CD31+CD45Flk-1+c-Kit+) in E8.5 Raldh2+/+;
RARE-lacZ+/ yolk sac. All population data were calculated as a percentage of total live cell population ± SEM (nR 3).
(C) Left chart indicates proportions of b-gal-negative (b-gal) and -positive (b-gal+) fractions within Raldh2+/+; RARE-lacZ+/ yolk sac endothelial cells; values
were calculated as percentage of CD31+CD45 live cells. Right chart depicts proportions of hemogenic and nonhemogenic endothelial cells within the b-gal+
subpopulation; values were calculated as percentage of b-gal+ CD31+CD45 live cells.
(D) qPCR analysis of hematopoietic gene expression in b-gal+ versus b-gal endothelial cells from pooled yolk sac tissues, calculated as gene expression relative
to endogenous b-actin expression ± SEM (nR 3).
(E) Hematopoietic potential of b-gal+ (b-gal+CD31+CD45) versus b-gal endothelial cells from E8.5 yolk sacs. Total number of CFU or multilineage CFU-GEMM
colonies generated are shown as percentage of seeded cells (300 cells) ± SEM (nR 3).
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off-target infected cells was 10%.
We quantified the restoration of candidate gene expression in
control (untreated) and LV-treated yolk sac endothelial cells at
48 hr postinfection. Untreated Raldh2/ mutants (Figure 2D,
No LV Mut) exhibited significantly reduced expression of c-Kit,
Runx1, and c-Myb relative to Raldh2+/+ controls. Treatment of
Raldh2/ embryos with c-Kit-, Runx1-, or c-Myb-LV restored
expression of each gene to wild-type levels, as did 3 ng/ml RA.
Importantly, we observed no deleterious phenotypes, increased506 Developmental Cell 27, 504–515, December 9, 2013 ª2013 Elsevspecification of hemogenic endothelium, or ectopic hematopoi-
esis in RA-treated or LV-infected wild-type embryos (Figure S1
available online).
c-Kit Functions Downstream of RA Signaling to Rescue
Hemogenic Endothelial Cell Specification
We evaluated the effects of re-expression of the candidate
genes in RA-deficient mutants on the presence of hemogenic
endothelial cells (Flk-1+c-Kit+CD45 SP cells) and multiline-
age hematopoietic progenitors (Flk-1c-Kit+CD45+ SP cells).ier Inc.
Figure 2. Infection of Raldh2–/– Mutant Yolk Sac with LV Encoding c-Kit, Runx1, or c-Myb
(A) Schematic diagram of the bicistronic lentiviral expression constructs encoding candidate gene cDNA cloned upstream of an IRES-ZsGreen1 reporter.
(B) Left panel: Control untreated (No LV) RA-deficient yolk sacs do not display ZsGreen1 fluorescence (green) 48 hr postinfection in whole embryo culture. Right
panel: Raldh2/ embryos infected with LV particles for c-Kit re-expression (c-Kit LV) display yolk sac endothelial cells expressing the ZsGreen1 reporter 48 hr
postinfection, as indicated by green cells lining the vasculature. Scale bars in all panels, 20 mm.
(C) Proportions of CD31+CD45 endothelial, CD45+ blood, and CD31+CD45Flk1+c-Kit+ hemogenic endothelial cells within ZsGreen1-expressing yolk sac
population. Values were calculated as percentage of ZsGreen1+ live cells.
(D) qPCR analysis of c-Kit, Runx1, and c-Myb gene expression in endothelial cells isolated from control untreated (No LV), RA-treated (RA), and LV-infected
mutant (Mut) yolk sacs versus untreated wild-type yolk sacs (No LV WT). Data points were calculated as gene expression relative to endogenous b-actin
expression ± SEM (nR 3).
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genitors (Figure 3D) were significantly decreased in RA-deficient
yolk sacs (Figures 3A and 3D, No LV Mut) relative to wild-type
controls (Figures 3A and 3D, No LV WT). Treatment of
Raldh2/ mutants with exogenous RA (Figures 3A and 3D, RA
Mut) significantly increased hemogenic endothelial and hemato-
poietic progenitor cell populations to wild-type frequencies.
LV-mediated re-expression of c-Kit in Raldh2/ mutants, but
notRunx1 or c-Myb, significantly increased hemogenic endothe-
lial cell numbers to wild-type levels (Figure 3A, c-Kit Mut) and
restored their multilineage hematopoietic colony-forming func-
tion (CFU-GEMM; Figure 3B), as well as erythroid and granulo-
cyte-macrophage colony-forming activity (Figure S2). Although
re-expression of c-Kit in Raldh2/ embryos increased hemato-
poietic progenitor formation above untreatedmutants (Figure 3D,
No LV Mut), it did not restore wild-type levels (Figure 3D,DevelopmNo LV WT). However, Runx1 was significantly increased upon
c-Kit re-expression in Raldh2/ mutants (Figure 3C), and its
re-expression uniquely rescued the production/propagation
of hematopoietic progenitor cells (Figure 3D), which was unaf-
fected by c-Myb re-expression.
c-Kit Regulates p27 Expression and Endothelial
Cell-Cycle Control
To confirm that c-Kit functions downstream of RA, we re-ex-
pressed c-Kit in Raldh2/; RARE-lacZ+/ embryos and found
that it failed to activate RA signaling (Figure 4A). In addition,
exogenous RA (0.5 mM all trans-RA [ATRA]) increased c-Kit pro-
tein expression in cultured endothelial cells by 1.6-fold within
24 hr (Figure S3).
We investigated whether c-Kit rescues hemogenic specifica-
tion in RA-deficient mutants by restoring endothelial cell-cycleental Cell 27, 504–515, December 9, 2013 ª2013 Elsevier Inc. 507
Figure 3. Re-expression of c-Kit inRaldh2–/–Mutants Restores Hemogenic Endothelial Cell Development and ItsMultilineageHematopoietic
Potential
(A–D) Quantitative analysis of (A) Flk-1+c-Kit+CD45 SP hemogenic endothelial cells and (D) Flk-1c-Kit+CD45+ SP hematopoietic progenitors from control
untreated (No LV), RA-treated (RA), and LV-infectedRaldh2/ (Mut) yolk sacs, compared with untreated wild-type yolk sac tissues (No LVWT). Data points were
calculated as percentage of total live cell population relative to untreated wild-type control (No LV WT) ± SEM (nR 3). (B) Hematopoietic potential of hemogenic
endothelial cells isolated from untreated, RA-treated, and LV-infected pooled mutant yolk sacs versus those pooled from wild-type untreated yolk sacs. Total
multilineage CFU-GEMM colonies generated are described as percentage of seeded cells (100 cells per well) ± SEM (nR 3). (C) qPCR analysis of Runx1 gene
expression in endothelial cells isolated from control untreated (No LV), RA-treated (RA), and LV-infected mutant (Mut) yolk sacs versus untreated wild-type yolk
sacs (No LV WT). Data points were calculated as gene expression relative to endogenous b-actin expression ± SEM (nR 3).
See also Figures S1 and S2.
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(Figure 4B, No LV Mut) contained significantly higher numbers
of endothelial cells relative to wild-type controls (Figure 4B, No
LV WT). Exogenous RA treatment (Figure 4B, RA Mut) and re-
expression of c-Kit (Figure 4B, c-Kit Mut) in Raldh2/ embryos
significantly reduced endothelial cell numbers compared to
untreated mutants.
We compared the cell-cycle distribution of endothelial cells
in E8.5 wild-type and Raldh2/ yolk sacs using pyronin Y and
Hoechst dyes to distinguish specific phases of cell cycle based
on relative RNA and DNA content. Compared to wild-type litter-
mates, Raldh2/ mutants exhibited a significantly increased
proportion of endothelial cells in the S/G2/M phase (25.5%
versus 35.8%, p = 0.004; Figure 4C) and significantly decreased
proportion in the G0 phase (8.8% versus 3.6%, p = 0.033). This
dysregulation of cell-cycle progression was rescued by exoge-
nous RA treatment of Raldh2/ mutants (25.5% versus 23.9%
cells in the S/G2/M phase, p = 0.356; and 8.8% versus 16.8%
cells in the G0 phase, p = 0.075 respectively; Figure 4C) and
by re-expression of c-Kit in Raldh2/ mutants (25.5% versus
26.4% cells in the S/G2/M phase, p = 0.637; and 8.8% versus
16.6% cells in the G0 phase, p = 0.014).
To elucidate the molecular pathway by which RA and c-Kit
regulate endothelial cell-cycle progression, we evaluated the
expression of known cell-cycle regulatory genes in endothelial
cells isolated from untreated, RA-treated, and c-Kit-rescued
Raldh2/ yolk sacs. Only expression of p27 was significantly
downregulated in E8.5 RA-deficient endothelial cells compared
to wild-type littermates (selected data are shown in Figure 4D).
Exogenous RA treatment of, and c-Kit re-expression in, RA-defi-
cient mutants restored p27 expression to wild-type levels
(Figure 4D).
p27 Functions Downstream of c-Kit to Regulate
Endothelial Cell-Cycle Control
To determine whether p27 functions downstream of c-Kit to
regulate endothelial cell-cycle progression, we infected cultured508 Developmental Cell 27, 504–515, December 9, 2013 ª2013 ElsevE7.5–E8.0 Raldh2/ embryos with LV encoding the p27 cDNA
(p27 Mut in Figure 5A), which increased p27 levels to wild-type
levels but did not affect c-Kit levels (Figure 5B). Re-expression
of c-Kit in Raldh2/ yolk sac endothelium also increased p27
expression to wild-type levels (Figure 5A, c-Kit Mut), suggesting
that p27 functions downstream of c-Kit.
Re-expression of p27 in Raldh2/ mutants significantly
reduced endothelial cell number (161.8% versus 130.8%, p =
0.012; Figure 5C), as well as increased the proportion of endo-
thelial cells in the G0 phase (3.6% versus 5.6%, p = 0.0318)
and decreased the proportion in the S/G2/M phase (35.8%
versus 22.9%, p = 0.0036) to wild-type levels (Figure 5D).
Re-expression of p27 in Raldh2/ mutants also rescued the
formation of hemogenic endothelial cells to wild-type levels
(Figure 5E).
Notch Signaling Mediates c-Kit-Induced Endothelial
Cell-Cycle Control and Hemogenic Specification
We examined whether Notch signaling mediates the effects
of c-Kit on endothelial cell proliferation, p27 expression, and
hemogenic endothelial cell specification. We inactivated Notch
signaling in cultured E7.5–E8.0 wild-type embryos using g-sec-
retase inhibitor DAPT (Larrive´e et al., 2012) (Figure 6A, DAPT
WT). We found that it significantly increased endothelial cell
numbers relative to untreated wild-type (Figure 6A, No LV WT;
p < 0.0001) and mutant (Figure 6A, No LV Mut; p < 0.0001) con-
trols. Notch inhibition also prevented c-Kit-mediated rescue
of endothelial cell numbers in Raldh2/ mutants (Figure 6A,
DAPT + c-Kit Mut), suppressed hemogenic endothelial cell for-
mation in wild-type embryos (Figure 6B, DAPT WT), and pre-
vented c-Kit-mediated rescue of hemogenic endothelial cell
specification in Raldh2/ mutants (Figure 6B, DAPT+c-Kit
Mut). Furthermore, we found that Notch inhibition suppressed
p27 expression in wild-type embryos (Figure 6D, DAPT WT) to
levels of untreated mutants (Figure 6D, No LV Mut), and c-Kit
re-expression in DAPT-treated Raldh2/ embryos failed to
restore p27 expression in the mutants (Figure 6D, DAPT + c-Kitier Inc.
Figure 4. c-Kit Re-expression in Raldh2–/– Mutants Restores Endothelial Cell Number, Cell-Cycle Distribution, and Expression of
Cyclin-Dependent Kinase Inhibitor p27
(A) Absence of blue-stained endothelial cells in X-gal-stained Raldh2/; RARE-lacZ+/ yolk sac treated with c-Kit-expressing LV. Scale bar, 20 mm.
(B) Quantitative FACS-based analysis of CD31+CD45 endothelial cells from control untreated (No LV), RA-treated (RA), and c-Kit LV-infected (c-Kit LV) mutant
yolk sacs versus control untreatedwild-type tissues (No LVWT), calculated as percentage of total live cell population relative to untreatedwild-type control (No LV
WT) ± SEM (nR 3).
(C) FACS-based cell-cycle analysis based on pyronin Y and Hoechst dye retention of endothelial cells from control and treatedmutant yolk sacs in comparison to
control wild-type tissues (No LV WT). Data points are calculated as percentage of total live endothelial cell population ± SEM (nR 3).
(D) qPCR analysis of cell-cycle related genes in CD31+CD45 endothelial cells from control and treated mutant yolk sacs versus control untreated wild-type yolk
sac tissue. Data were calculated as gene expression relative to endogenous b-actin expression ± SEM (nR 3).
See also Figure S3.
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wild-type levels in c-Kit-rescued Raldh2/ embryos (Figure 6C,
DAPT + c-Kit Mut).
To determine which components of the Notch signaling
pathway may be mediating these effects, we quantified the
expression of Notch receptors, ligands, and downstream effec-
tors in endothelial cells isolated from E8.5 embryos cultured in
control or experimental conditions. We found that the expres-
sion of Notch1 and downstream targets Hes1 and Hey1 were
specifically and significantly downregulated in Raldh2/ yolk
sac endothelial cells (Figure 6E, No LV Mut) compared to
wild-type controls (Figure 6E, No LV WT). Treatment of
Raldh2/ embryos with RA, and re-expression of c-Kit therein,
significantly increased the expression of all three genes (Fig-
ure 6E, RA Mut and c-Kit Mut, respectively). Inhibition of Notch
signaling in wild-type embryos (Figure 6E, DAPTWT) downregu-
lated Notch1, Hes1, and Hey1 expression to levels of untreated
mutants (Figure 6E, No LV Mut) and prevented their upregula-
tion in response to c-Kit re-expression (Figure 6E, DAPT +
c-Kit Mut).
p27 Mediates Notch Regulation of Hemogenic
Endothelial Cell Specification
We investigated whether p27 is the critical effector of Notch
signaling that enables hemogenic specification of primordial
endothelium. We inactivated Notch signaling in cultured
E7.5–E8.0 wild-type embryos using DAPT (Figure 6F, DAPT
WT), which significantly inhibited p27 expression (Figure 6D),Developmhemogenic endothelial cell formation (Figures 6B and 6F), and
subsequent production of hematopoietic progenitors (Figure 6G)
relative to wild-type controls. We then re-expressed p27 in
DAPT-treated wild-type embryos and found that the develop-
ment of hemogenic endothelial cells and generation of hemato-
poietic progenitors was restored to wild-type levels (Figures 6F
and 6G, DAPT + p27 WT). Thus, p27 mediates the specification
of functional hemogenic endothelial cells downstream of Notch
signaling.
Defining Hemogenic Endothelial Cells within the
Embryonic Aorta-Gonad-Mesonephros
To determine whether the signaling hierarchy regulating the
specification of hemogenic endothelial cells in the yolk sac
also regulates this process within the embryo proper, we first
defined the phenotype of hemogenic endothelial cells within
the embryonic aorta-gonad-mesonephros (AGM) region (de-
noted in Figure S4A), the first site of intraembryonic definitive
hematopoiesis.
Multilineage Colony-Forming Potential in the AGM Is
Restricted to the SP
Since yolk sac hemogenic endothelial cells, and adult HSCs,
exhibit an SP phenotype (Goldie et al., 2008; Nadin et al.,
2003), we first investigated whether the murine AGM harbored
SP cells that exhibited blood-forming potential. We isolated SP
cells from E9.5–E11.5 embryonic AGM (denoted in Figure S4B)
and found that they were highly enriched for hematopoieticental Cell 27, 504–515, December 9, 2013 ª2013 Elsevier Inc. 509
Figure 5. Re-expression of p27 in Raldh2–/– Mutants Rescues Specification and Function of Hemogenic Endothelial Cells
(A and B) qPCR analysis of (A) p27 and (B) c-Kit gene expression in endothelial cells isolated from untreated (No LV) and LV-infected (c-Kit and p27) Raldh2/
mutant (Mut) yolk sacs versus untreated wild-type yolk sac (No LV WT). Data points were calculated as gene expression relative to endogenous b-actin
expression ± SEM (nR 3).
(C) Quantitative FACS-based analysis of CD31+CD45 endothelial cells from control untreated (No LV) and p27 LV-infected (p27) mutant yolk sacs versus
control untreated wild-type tissues (No LV WT), calculated as percentage of total live cell population relative to untreated wild-type control (No LV WT) ± SEM
(nR 3).
(D) FACS-based cell-cycle analysis based on pyronin Y and Hoechst dye retention of endothelial cells from control and p27 LV-infected mutant yolk sacs relative
to endothelial cells from control wild-type tissues (No LV WT). Data points are calculated as percentage of total live endothelial cell population ± SEM (nR 3).
(E) Quantitative analysis of hemogenic endothelial cells from untreated (No LV) and p27 LV-infected (p27 LV) mutant yolk sacs, in comparison to untreated wild-
type yolk sac tissues (No LVWT). Data points were calculated as a percentage of total live cell population relative to untreatedwild-type control (No LVWT) ± SEM
(nR 3).
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formation of multilineage colonies (GEMM) was maximal at
E10.5, coincident with the peak of AGM definitive hematopoiesis
(Medvinsky and Dzierzak, 1996; Mu¨ller et al., 1994), and
restricted to the SP fraction.
Subfractionation of the AGM SP Defines Blood-Forming
Cell Phenotypes
To further define the phenotype of hemogenic endothelial cells
and multilineage hematopoietic progenitors within the AGM
SP, we assessed the relative hematopoietic activity of SP cells
expressing Flk-1 and VE-cadherin (endothelial cell markers),
CD31 (expressed by both endothelial and blood cells), c-Kit
(stem/progenitor cell marker), and CD41 and CD45 (hematopoi-
etic markers). We found that multilineage colony-forming activity
was restricted to CD31+, VE-cadherin+, c-Kit+, CD41+, and
CD45+ SP cells (Figure 7B) and was observed in both Flk-1+
and Flk-1 SP cells.510 Developmental Cell 27, 504–515, December 9, 2013 ª2013 ElsevClonal Analysis Reveals that Flk-1+c-Kit+CD45– AGM SP
Cells Are Aortic Hemogenic Endothelial Cells
As it is in the yolk sac (Goldie et al., 2008), we found expression
of Flk-1 and CD45 to be mutually exclusive in the AGM SP (Fig-
ure S4B). Therefore, to define AGM hemogenic endothelial cells
and hematopoietic progenitors at the clonal level, we sorted
E10.5 AGM SP cells based on Flk-1 and c-Kit expression
(Figure 7C) and subjected them to established single-cell
colony-forming assays (Goldie et al., 2008). Clonal assays
demonstrated that both Flk-1+c-Kit+CD45 SP cells and Flk-
1c-Kit+CD45+ SP cells gave rise to multilineage colonies (Fig-
ure 7C). However, only Flk-1+c-Kit+CD45 SP cells were
adherent in culture, producing a monolayer of endothelial cells
exhibiting cobblestone morphology and DiI-AcLDL uptake
(selected data are shown in Figure 7C). Although some myeloid
progenitors can also exhibit these characteristics, they also ex-
press CD45 and do not give rise to multilineage hematopoietic
colonies in vitro. Furthermore, although HSCs can also generateier Inc.
Figure 6. Notch Signaling Regulates Primordial Endothelial Cell Proliferation and Hemogenic Specification in Wild-Type and RA-Deficient
Mutants Re-expressing c-Kit
(A) Quantitative FACS-based analysis of CD31+CD45 endothelial cells from control untreated (No LV), c-Kit LV-infected (c-Kit), DAPT-treated + c-Kit LV-infected
(DAPT + c-Kit) Raldh2/mutant, and DAPT-treated (DAPT) wild-type yolk sacs versus control untreated wild-type tissues (No LVWT), calculated as percentage
of total live cell population relative to untreated wild-type control (No LV WT) ± SEM (nR 3).
(B) Quantitative analysis of Flk-1+c-Kit+CD45 SP hemogenic endothelial cells from control untreated (No LV), c-Kit LV-infected (c-Kit), DAPT-treated + c-Kit LV-
infected (DAPT + c-Kit) Raldh2/mutant, and DAPT-treated (DAPT) wild-type yolk sacs versus control untreated wild-type tissues (No LVWT). Data points were
calculated as a percentage of total live cell population relative to untreated wild-type control (No LV WT) ± SEM (nR 3).
(C–E) In (C), qPCR analysis is shown of c-Kit expression in CD31+CD45 endothelial cells from untreated control (No LV), c-Kit LV-infected (c-Kit), and DAPT-
treated + c-Kit LV-infected (DAPT + c-Kit) Raldh2/ mutant (Mut) yolk sacs versus untreated wild-type yolk sac tissue (No LV WT). (D) shows qPCR analysis of
p27 expression in CD31+CD45 endothelial cells from untreated (No LV), c-Kit LV-infected (c-Kit), DAPT-treated + c-Kit LV-infected (DAPT + c-Kit) Raldh2/
mutant (Mut) and DAPT-treated (DAPT) wild-type yolk sacs versus untreated wild-type yolk sac tissue (No LV WT). (E) shows qPCR analysis of Notch1 and
transcription factors Hes1 and Hey1 in CD31+CD45 endothelial cells from control and treated mutant yolk sacs versus that from untreated wild-type yolk sac
tissue. In (C) through (E), data were calculated as gene expression relative to endogenous b-actin expression ± SEM (nR 3).
(F and G) Quantitative analysis of (F) Flk-1+c-Kit+CD45 SP hemogenic endothelial cells and (G) Flk-1c-Kit+CD45+ SP hematopoietic progenitor cells from
untreated control (No LV), DAPT-treated (DAPT), and DAPT-treated + p27 LV-infected (DAPT + p27) wild-type yolk sacs versus untreated wild-type tissues (No
LV WT). Data points were calculated as a percentage of total live cell population relative to untreated wild-type control (No LV WT) ± SEM (nR 3).
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Flk-1 (Jackson et al., 2001) and are not adherent in culture.
Thus, Flk-1+c-Kit+CD45 SP cells do not represent hemato-
poietic stem or progenitor cells; rather, they are endothelial cells
with blood-forming potential, and expression of c-Kit both
defines and is necessary for their hematopoietic activity
(Figure 7B).
AGM Hemogenic Endothelial Cells Are Enriched for
Effectors of RA and Notch Signaling and Expression of
p27
We next examined whether AGM hemogenic endothelial cells
were enriched for RA signaling. We isolated Flk-1+c-Kit+CD45
SP cells from E10.5 Raldh2+/+; RARE-lacZ+/ AGM and demon-
strated that 93.3% were b-gal+ (Figure S5; summarized in
Figure 7D); only 1%–5% of the NSP cells within the AGM were
b-gal+.
In addition, we evaluated the relative expression of RA recep-
tors (RARa and RARb) and signaling targets (RARb), NotchDevelopmsignaling components (Notch1, Hes1, Hey1) and cell-cycle reg-
ulators (p21, p27) in E10.5 AGM hemogenic (Flk-1+c-Kit+CD45
SP cells) and nonhemogenic (CD31+CD45 NSP cells) endothe-
lial cells. AGM hemogenic endothelial cells were highly enriched
for expression of RA signaling target and receptor RARb, as well
as RARa, which mediates RA regulation of endothelial cell-cycle
progression (Bohnsack et al., 2004). AGM hemogenic endo-
thelial cells were also highly enriched for Notch1 and Notch
effectorsHes1 andHey1, as well as p21 and p27, relative to non-
hemogenic AGMendothelial cells. Thus, like yolk sac hemogenic
endothelial cells, those derived from the AGM exhibit active RA
and Notch signaling and are highly enriched for cell-cycle regu-
lators p21 and p27.
DISCUSSION
Although recent studies have provided direct evidence of an
endothelial origin for blood cells (Goldie et al., 2008; Bertrand
et al., 2010; Boisset et al., 2010; Kissa and Herbomel, 2010;ental Cell 27, 504–515, December 9, 2013 ª2013 Elsevier Inc. 511
Figure 7. Hemogenic Endothelial Cells from E10.5 AGM Are RA Responsive, Require c-Kit for Hematopoietic Function, and Are Enriched for
Expression of p27 and Notch Signaling Pathway Components
(A) Hematopoietic potential of SP and non-SP (NSP) fractions isolated from E9.5–E11.5 AGM relative to that E9.5 yolk sac SP cells, which serve as positive
control, in methylcellulose colony formation assays. Individual colony types were scored as erythroid (E), granulocyte-macrophage (GM), and granulocyte-
erythroid-macrophage-megakaryocyte (GEMM) CFU. Total number of colonies generated are reported per 1,000 seeded cells ± SEM (nR 3).
(B) Hematopoietic potential of selected cell surface-marker-expressing cells within the SP fraction of the E10.5 AGM. Total multilineage GEMM colonies
generated are reported per 100 seeded cells ± SEM (nR 3).
(C) Clonal assay and time course of (top panels) Flk-1+c-Kit+CD45 SP and (bottom panels) Flk-1c-Kit+CD45+ SP cell development. Scale bars represent 10 mm
(days 1 and 3) and 50 mm (days 5–7).
(D) Proportions of b-gal-negative (b-gal) and -positive (b-gal+) fractions within E10.5 Raldh2+/+; RARE-lacZ+/ AGM hemogenic endothelial cells; values were
calculated as percentage of live Flk-1+c-Kit+CD45 SP cells.
(E) qPCR analysis of RA signaling (RARa and RARb) and Notch signaling (Notch1, Hey1, and Hes1) pathway genes, as well as of cell-cycle-related (p21 and p27)
genes, in hemogenic endothelial cells (HemEC) versus non-HemEC cells isolated from E10.5 wild-type AGM tissues. Gene expression was calculated relative to
endogenous b-actin expression ± SEM (nR 3).
See also Figures S4 and S5.
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events that lead to the induction of hematopoietic potential
within a subset of vascular endothelium.
We previously demonstrated that RA signaling is required
for hemogenic specification of primordial endothelial cells
(Goldie et al., 2008). Currently, we determined that >90% of
RA-responsive endothelial cells in the yolk sac and AGM
exhibited a hemogenic phenotype and that >90% of yolk sac
and AGM hemogenic endothelial cells, which we defined on a
clonal level, exhibited active RA signaling.We further determined
that not only is c-Kit a marker of hemogenic endothelial cell
phenotype in both tissues, but it is also required downstream
of RA to enable their development. Runx1 was upregulated
downstream of c-Kit and specifically rescued hematopoietic
progenitor cell formation and/or propagation in RA-deficient mu-
tants, which is consistent with other studies demonstrating the
requirement of Runx1 for definitive hematopoietic stem/progen-
itor cell development (Chen et al., 2009; Liakhovitskaia et al.,
2009; North et al., 1999, 2002). Thus, these data collectively sug-
gest that c-Kit and Runx1 regulate different steps in the develop-
mental transition from primordial/nonhemogenic endothelium to
multilineage hematopoietic stem/progenitor cells; c-Kit regu-
lates the specification of hemogenic endothelium, whereas512 Developmental Cell 27, 504–515, December 9, 2013 ª2013 ElsevRunx1 regulates the generation and/or propagation of multiline-
age hematopoietic stem/progenitor cells from specified hemo-
genic endothelial cells.
We found that, in addition to regulating the hemogenic speci-
fication of primordial endothelial cells, c-Kit also regulates their
cell-cycle progression. Although c-Kit has been previously impli-
cated in the regulation of proangiogenic factors (Elmasri et al.,
2012) and cytokine-induced endothelial cell morphogenesis, its
role in endothelial cell proliferation had not been defined. We
found that c-Kit regulated cell cycling of endothelium via upregu-
lation of p27. Genetic ablation of p27 yields mice that exhibit
increased cellularity of the liver, spleen, and thymus and
increased proliferation of hematopoietic progenitor cells in
bone marrow and spleen (Fero et al., 1996). Recent studies
have also shown that miR-221 represses p27 and c-Kit expres-
sion in endothelial cells (Liu et al., 2012) to promote endothelial
tip cell proliferation and migration during angiogenesis (Nicoli
et al., 2012).
Other angiogenic processes such as tip-stalk cell specifica-
tion (Hellstro¨m et al., 2007; Suchting et al., 2007) and arterial-
venous differentiation (Lanner et al., 2007; Lawson et al., 2001)
are dependent on Notch signaling, and its disruption results in
hyperproliferation of endothelial cells (Hellstro¨m et al., 2007;ier Inc.
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defects (Krebs et al., 2000), and arteriovenous malformations
(Krebs et al., 2010; Kim et al., 2008; Lanner et al., 2007). More-
over, arterial specification may be required for definitive hemato-
poiesis within aortic endothelium (Burns et al., 2009; Kumano
et al., 2003). We therefore investigated whether Notch signaling
functions downstream of c-Kit to regulate endothelial cell-cycle
progression and hemogenic specification. We found that Notch
inhibition resulted in decreased p27 expression, increased endo-
thelial cell proliferation, and impaired hemogenic endothelial cell
development in wild-type and c-Kit-rescued Raldh2/ yolk
sacs. Re-expression of p27 in RA-deficient and Notch-
inactivated primordial endothelial cells was sufficient to rescue
endothelial cell-cycle defects and enable hemogenic specifica-
tion. This signaling hierarchy likely also regulates the specifica-
tion of intraembryonic hemogenic endothelial cells within the
AGM, given that RA and Notch signaling components, as well
as p27, were highly enriched therein.
Our studies not only define the critical signaling hierarchy
downstream of RA that regulates hemogenic endothelial cell
specification but also reveal a fundamental link between the
regulation of endothelial cell-cycle progression and the acquisi-
tion of functionally specialized phenotypes. In support of this
concept, recent studies in other fields suggest that cell-cycle
duration is a critical determinant of pluripotency (Hindley and
Philpott, 2013) and cell fate (Kueh et al., 2013). In addition,
cell-cycle regulators such as p27 have been shown to directly
repress the expression of genes that promote pluripotency (Li
et al., 2012). Therefore, it is possible that p27 expression by pri-
mordial endothelial cells serves to repress genes that promote/
sustain an immature (multipotent) state, while p27-mediated
elongation of G1 phase enables the expression of genes that
specify distinct endothelial cell subtypes. Continued work in
this area is clearly needed and will be critically important for
the field; insights gained will significantly advance our under-
standing of normal vascular development and enable optimiza-
tion of clinical therapies for vascular disorders and regenerative
medicine applications.EXPERIMENTAL PROCEDURES
Animal Studies and Genotyping
Threemousemodels were used: (1)Raldh2-deficient mice (Niederreither et al.,
1999); (2) mice expressing the hsplacZ transgene downstream of RA response
element (Rossant et al., 1991); and (3) Raldh2+/ bred to RARE-lacZ+/mice to
generate animals heterozygous for both Raldh2 and hsplacZ (Raldh2+/;
RARE-lacZ+/). All lines were maintained via heterozygous sibling matings,
and viable offspring were genotyped by PCR. Genomic DNA was isolated
via digestion of tail clippings with proteinase K at 37C overnight, followed
by phenol-chloroform extraction and resuspension in Tris-EDTA buffer.
Embryos were obtained via timed matings, with the morning of the detection
of a vaginal plug designated as E0.5. Genotyping of embryos was performed
using genomic DNA isolated from whole tissue lysates as described (Goldie
et al., 2008). PCR for detection of the disrupted Raldh2 gene was performed
using primers flanking the gene locus (Niederreither et al., 1999), and
Platinum Pfx DNA Polymerase (Invitrogen). Primers targeting the RARE-lacZ
transgene (forward primer: 50CAGACGATGGTGCAGGATAT30; reverse primer:
50ATACAGCGCGTCGTGATTAG 30) were amplified with Taq DNA Polymerase
(Invitrogen) to generate a 300-base-pair fragment in transgenic animals. All
animal experiments were approved by the Baylor College of Medicine and
Yale University Institutional Animal Care and Use Committees.DevelopmHistology and Immunohistochemistry
For lacZ staining of tissues, embryos were dissected, individually genotyped,
fixed in 0.2% glutaraldehyde for 30 min at room temperature (RT), and incu-
bated in X-gal staining solution (Gossler et al., 1989) overnight at 37C in the
dark. Tissues were postfixed in 4% paraformaldehyde for 2–4 hr at RT,
immersed in 10%–30% WT/vol sucrose gradient infusion, embedded in
optimal cutting temperature compound (Sakura Finetek USA), quick-frozen
in liquid nitrogen, and sectioned at 10 mm. Eosin was used for counterstaining.
For immunohistochemistry, embryos were cryosectioned and sections
blocked for 4–6 hr at RT with 10% normal donkey serum (NDS)/0.5% BSA/
PBS. Standard immunohistochemistry methods were followed using rat anti-
mouse CD31 antibodies (1:100; BD Biosciences) diluted in 10% NDS/0.5%
BSA/PBS and incubated overnight at 4C. Sections were subsequently incu-
bated for 2 hr at RT with goat anti-rat Alexa Fluor 633 secondary antibodies
(1:500; Molecular Probes) diluted in 10% NDS/0.5%BSA/PBS. Nuclear stain-
ing was performed with DAPI, and sections were mounted in Mowiol. Images
were captured with a Zeiss AxioObserver microscope fitted with an AxioCam
MRm camera, using Zeiss AxioVision software, version 4.8.2.0 (Carl Zeiss
MicroImaging).
Reverse Transcription and qPCR
Quantitative analysis of gene expression was performed using TaqMan Gene
Expression Assay primer-probe sets (Applied Biosystems). Freshly dissected
yolk sac or AGM tissues were individually genotyped and subjected to FACS
for cell-specific isolation. RNA was isolated using the Arcturus PicoPure
RNA Isolation Kit (Applied Biosystems). The SuperScript II First Strand Synthe-
sis kit (Invitrogen) was used to reverse-transcribe 1 mg total RNA at 42C for
50 min. qPCR was performed using 1 ml of the reverse transcription reaction
product together with TaqMan Universal PCR Reaction Mix (Applied Bio-
systems). All gene expression assays were performed in triplicate using at
least three independently isolated RNA samples, and the resulting data
normalized to endogenous b-actin expression.
Flow Cytometry and FACS
Single-cell suspensions were prepared from freshly dissected, individually
genotyped, and pooled tissues. Yolk sacs were digested at 37C for 30 min
in 0.05% collagenase type II (Sigma-Aldrich), prepared in Hank’s balanced
salt solution (HBSS) containing 10% fetal bovine serum (FBS). AGM tissues
were digested at 37C for 20–30 min in 0.1% collagenase type II solution. Tis-
sue digests were homogenized by trituration with a 26-gauge needle and 1 ml
syringe, as described elsewhere (Goldie et al., 2008), and stained accordingly.
For detection of b-gal-expressing cells, amodification of standard published
methods for FACS-Gal assay was performed (Nolan et al., 1988). Single-cell
suspensions were stained with 50 mM fluorescein di-b-D-galactopyranoside
(FDG; Invitrogen) for 15 min at 37C. For isolation of SP cells, Hoechst staining
of yolk sac or AGM tissues was performed using established protocols
(Goodell et al., 1996; Nadin et al., 2003). Following tissue digestion and tritura-
tion, cells were stained with 5 mg/ml Hoechst 33342 (Sigma-Aldrich) for 1 hr at
37C. For analysis of cell-cycle distribution of cells based on cellular DNA and
RNA content, single-cell suspensions were stained with 10 mg/ml Hoechst
33342 at 37C for 45 min, followed by addition of 1 mg/ml pyronin Y (Sigma-
Aldrich) for 15min. Cells were subsequently stained with various combinations
of the following rat anti-mouse antibody conjugates: CD31-allophycocyanin
(APC), CD45-APC-Cy7, Flk-1-phycoerythrin (PE), c-Kit-APC, CD41-fluores-
cein isothiocyanate (all 1:100; BD Biosciences) and c-Kit-PE-Cy7 (1:100;
eBioscience). Unconjugated rat anti-mouse VE-cadherin antibodies (BD
PharMingen) were added at a 1:100 dilution for 20 min on ice, followed by in-
cubation with donkey anti-rat Alexa Fluor 488 immunoglobulin G secondary
antibodies (Vector Laboratories) at 1:500 for 20 min on ice. Single-cell suspen-
sions were washed and resuspended in HBSS/10% FBS with 10 mg/ml
propidium iodide (Sigma-Aldrich), followed by FACS using a FACSAria (BD
Biosciences) cell sorter.
Multilineage Hematopoietic Colony-Forming Assay
Freshly isolated and genotyped yolk sac and AGM tissues were pooled,
digested with collagenase to generate single-cell suspensions, and stained
with mouse-specific antibodies and FDG or Hoechst 33342. To assess the
hematopoietic potential of distinct yolk sac or AGM populations, we isolatedental Cell 27, 504–515, December 9, 2013 ª2013 Elsevier Inc. 513
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M3434 medium (StemCell Technologies) in fibronectin-coated 48-well tissue
culture plates (BD BioCoat, BD Biosciences). All cultures were incubated at
37C with 5% CO2 and scored for colony formation at days 1, 3, 5, 7, 10,
and 14 as described elsewhere (Goldie et al., 2008; Nadin et al., 2003).
In Vivo Restoration of RA Signaling
Phenotypic rescue of RA signaling in utero was achieved by supplementing
maternal diet with ATRA (Sigma-Aldrich). Beginning at E7.5 through
E9.5 days postcoitum, pregnant Raldh2+/; RARE-lacZ/, and Raldh2+/;
RARE-lacZ+/ dams were fed standard rodent chow supplemented with
100 mg/g ATRA, as described elsewhere (Lai et al., 2003). Embryos were
harvested at E9.5, genotyped, and fixed for histologic analysis.
Construction of Lentiviral cDNA Vectors and LV Generation
Full-length mouse c-Kit, Runx1, and c-Myb cDNA were individually cloned
from midgestation murine yolk sac genomic DNA using Platinum Pfx DNA







Amplified c-Kit, Runx1, and c-Myb coding fragments were inserted into
the HIV-1-based lentiviral expression vector pLVX-IRES-ZsGreen1 (Clontech
Laboratories) using appropriate restriction sites and the Quick Ligation Kit
(New England Biolabs). One-Shot Stbl3 chemically competent E. coli
(Invitrogen) were transformed with each lentiviral expression vector. Correct
clones were screened for accurate insertion of c-Kit, Runx1, and c-Myb
cDNA cassettes by restriction enzyme digestion and DNA sequencing.
Large-scale preparation of plasmid DNA for transfection into virus packaging
293T cells was performed using the PureLink HiPure Plasmid Filter Maxi Prep
Kit (Invitrogen).
Packaging and synthesis of VSV-G-pseudotyped recombinant LV
particles was performed using the Lenti-X HT Packaging System (Clontech
Laboratories). High-titer LV particles for re-expression of p27 (Cdkn1B;
GenBank accession number AM393634) in mutant Raldh2 embryos were
purchased from Open Biosystems in lyophilized form and resuspended in
Dulbecco’s modified Eagle’s medium (DMEM) according to the manufac-
turer’s protocol. All LV particles were titrated via transduction of C166 yolk
sac endothelial cells, followed by FACS to detect ZsGreen1 or GFP fluorescent
reporter expression.
Whole Mouse Embryo Culture and Ex Vivo Phenotypic Rescue
Studies
E7.5 embryos were dissected in 10% PBS, with yolk sac integrity carefully
maintained and Reichert’s membrane removed. For rescue experiments,
embryos were preincubated in one of the following reagents for 2 hr at 37C:
DMEM containing 3 ng/ml ATRA (Sigma-Aldrich) suspended in 100% ethanol,
DMEM containing 2mM DAPT (Sigma-Aldrich) suspended in DMSO (Sigma-
Aldrich), or LV particles for re-expression of c-Kit,Runx-1, c-Myb, or p27. Con-
trol treatments included preincubation of embryos in DMEM alone and DMEM
supplemented with 3 ng/ml ATRA. Embryos with intact yolk sacs were main-
tained in rolling culture (BTC Precision Engineering) in whole rat serum for
up to 48 hr at 37C and protected from light exposure. ATRA (3 ng/ml) was
added directly to the culturemedium. Upon initiation of culture, embryo bottles
were gassed for 3 min with 5% CO2 and then gassed again after 24 hr culture
for 3 min with 20% CO2.
Statistical Analyses
At least three biological replicates were used for each data point and for
derivation of error bars and SEM for qPCR, hematopoietic colony-formation
assays, and FACS-based population analysis experiments. Statistical analysis
of significance was determined by two-way ANOVA or Student’s t test with a
confidence interval of 95% (p% 0.05).514 Developmental Cell 27, 504–515, December 9, 2013 ª2013 ElsevSUPPLEMENTAL INFORMATION
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